The IPO of Sudeep Pharma Ltd commenced with significant interest on Friday, achieving full subscription on the first day. Priced between Rs 563 and Rs 593, the offering experienced a surge in demand from retail and high-net-worth investors, surpassing the one-time subscription mark despite limited institutional participation.
The public issue was oversubscribed by a little over one time, with the retail segment surpassing its quota comfortably. Non-institutional investors also contributed to the early momentum, while the qualified institutional buyers’ quota remained stagnant at around eight percent.
Observers noted a common trend in mid-sized IPOs where retail investors drive initial demand, with institutions tending to participate closer to the closing date. The grey market premium ranged between Rs 111 and Rs 130, suggesting a potential listing in the Rs 700–715 range, reflecting an 18-20% premium over the upper price band.
Optimism surrounding the company is fueled by its strong anchor book, as Sudeep Pharma raised approximately Rs 268 crore from anchor investors before the public offering, indicating early confidence from some institutions. The company specializes in supplying excipients and mineral-based ingredients to pharmaceutical and nutraceutical manufacturers, exhibiting consistent growth and stable margins, which attracted retail interest early on.
However, concerns have been raised by analysts regarding the significant portion of the offer being an offer-for-sale of nearly Rs 800 crore, implying that most proceeds will benefit existing shareholders rather than funding expansion. Some market watchers also find the valuation at the upper price band to be expensive. The lack of substantial participation from qualified institutional buyers on the first day suggests that long-term conviction may only become apparent closer to the issue’s closure.
While short-term investors may find encouragement in the grey market premium trend and early subscription numbers, long-term investors may prefer to wait and assess institutional demand on the final day before making decisions. The IPO is open until November 25, with the upcoming sessions determining whether Sudeep Pharma can sustain the momentum it has garnered.
(Note: The opinions expressed in this article are personal and do not represent the views of any organization. It is advised to consult with financial experts before making investment decisions.)